Ozempic & Wegovy Shortage 2026: Current Status & What To Do

The Ozempic and Wegovy shortage has been one of the most talked-about pharmaceutical stories of the past two years. Here is what is actually happening in 2026, why it keeps occurring, and what your options are if you cannot get your medication.

Why Is There an Ozempic Shortage?

The GLP-1 medication shortage stems from a collision of supply and demand that manufacturers were not prepared for. Demand for semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) has grown far faster than Novo Nordisk and Eli Lilly’s manufacturing capacity. Building new pharmaceutical manufacturing facilities takes years and billions of dollars — demand spiked in months.

Social media — particularly TikTok and celebrity endorsements — dramatically accelerated adoption beyond what any pharmaceutical forecast anticipated. Off-label prescribing for weight loss (Ozempic is approved for diabetes, Wegovy for weight management) further stretched supply.

What Is the Situation in 2026?

Both Novo Nordisk and Eli Lilly have invested heavily in manufacturing expansion since 2023. Supply has improved significantly compared to 2023–2024 shortage peaks, but availability remains inconsistent. Some doses and pen types remain easier to find than others, and shortages are still reported by patients and pharmacies across the US.

What to Do If You Cannot Get Your Prescription Filled

If your pharmacy does not have your dose in stock, try calling multiple pharmacies including independent pharmacies, which sometimes have better access than large chains. Mark Cuban’s Cost Plus Drugs and similar discount pharmacies are worth checking. Ask your prescriber about dose adjustments that might be available in stock. Some physicians can prescribe a different GLP-1 medication (tirzepatide, liraglutide) as a temporary bridge.

Compounded Semaglutide: The Shortage-Proof Alternative

The most practical solution for many people affected by the shortage has been switching to compounded semaglutide through a telehealth platform. Compounding pharmacies are not subject to the same supply constraints as brand-name manufacturers — they compound the medication in-house from the active ingredient.

This means compounded semaglutide has generally been available throughout the shortage period when brand-name versions were not. It is also significantly cheaper, at $149–$299/month vs $900–$1,400 for brand Ozempic without insurance.

📌 See also: Ozempic face — what it is and how to avoid it

This article contains affiliate links. We may earn a commission at no extra cost to you. See our Affiliate Disclosure. For up-to-date shortage information, always check with your pharmacy and prescriber.

Current Status: Is There Still a Semaglutide Shortage in 2026?

The semaglutide shortage situation changed significantly in 2025:

• FDA removed semaglutide from the shortage list in mid-2025, declaring supply had caught up with demand for both Ozempic and Wegovy
• Compounded semaglutide legally ended — 503A and 503B compounding pharmacies were no longer permitted to compound semaglutide once it left the shortage list
• Tirzepatide (Mounjaro/Zepbound) was also removed from shortage status in 2025
• Real-world availability improved substantially, though some specific doses (particularly higher doses like Ozempic 2 mg and Wegovy 2.4 mg) still see occasional localized pharmacy shortages

As of early 2026, most patients in major metro areas can fill prescriptions without significant delays. Rural areas and certain high-demand pharmacies may still have occasional wait times.

Why the Shortage Happened in the First Place

The GLP-1 shortage of 2022–2025 was driven by an unprecedented convergence of factors:

• FDA approval of Wegovy for obesity opened GLP-1 use beyond the diabetic population — the addressable market grew 5–10x overnight
• Novo Nordisk and Eli Lilly had not built manufacturing capacity for this demand level
• Viral social media coverage (Ozempic face, celebrity use) created a demand surge no one predicted
• The active pharmaceutical ingredient (semaglutide) is complex to manufacture — scaling takes years, not months
• Pen assembly and fill-finish operations became bottlenecks even after API production increased

What To Do If Your Pharmacy Still Can’t Get Your Dose

Even with improved supply, localized shortages still occur. Here’s how to navigate them:

• Call multiple pharmacies — CVS, Walgreens, Costco, independent pharmacies, and specialty pharmacies may have different stock. Don’t just check one.
• Use the manufacturer’s pharmacy locator — Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) have online tools to locate stocked pharmacies.
• Ask your doctor about dose flexibility — If your usual dose is unavailable, your doctor may authorize a lower dose temporarily rather than going without entirely.
• Consider mail-order pharmacy — Mail-order pharmacies often have better supply chain predictability for specialty medications.
• LillyDirect for tirzepatide — Eli Lilly sells Zepbound vials directly to patients at $399–$549/month, bypassing traditional pharmacy supply chains.

Frequently Asked Questions

Can I still get compounded semaglutide in 2026?

With semaglutide off the FDA shortage list, standard compounding of semaglutide is no longer legally permitted under federal rules. Some telehealth platforms may still claim to offer “compounded” options — verify the legal status carefully. Personalized compounding for patients with a documented allergy or intolerance to specific inactive ingredients may still be possible through 503A pharmacies on a case-by-case basis.

Is the Wegovy shortage over for higher doses?

Mostly, but higher doses (1.7 mg and 2.4 mg) are more frequently out of stock at any given pharmacy than starter doses. If you’re titrating up and your pharmacy doesn’t stock higher doses consistently, establishing a relationship with a specialty pharmacy or mail-order service is the most reliable solution.

Will GLP-1 prices drop now that the shortage is over?

Not significantly in the near term — prices are driven by patent protection and manufacturer pricing decisions, not supply. Novo Nordisk and Eli Lilly have maintained list prices. Generic semaglutide won’t be available until patents expire (post-2026 at the earliest). The main price relief pathway is expanded insurance coverage, not generics.